Atlas Trials

Phase II Study of Pembrolizumab After Curative Intent Treatment for Oligometastatic Non-Small Cell Lung Cancer

Clinical trial NCT02316002 · COMPLETED

Trial details

NCT number
NCT02316002
Sponsor
Abramson Cancer Center at Penn Medicine
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Oligometastatic Non-small Cell Lung Cancer (NSCLC)
Start date
2015-01-21
Primary completion
2018-09-30
Enrollment
51

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.